Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
158.73
-4.33 (-2.66%)
At close: Apr 28, 2026, 4:00 PM EDT
159.33
+0.60 (0.38%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Belite Bio Employees
Belite Bio had 41 employees as of December 31, 2025. The number of employees increased by 16 or 64.00% compared to the previous year.
Employees
41
Change (1Y)
16
Growth (1Y)
64.00%
Revenue / Employee
n/a
Profits / Employee
-$1,892,951
Market Cap
6.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41 | 16 | 64.00% |
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Arcellx | 209 |
| Celcuity | 155 |
| Protagonist Therapeutics | 132 |
BLTE News
- 6 days ago - Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th - GlobeNewsWire
- 4 weeks ago - Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - GlobeNewsWire
- 2 months ago - Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
- 5 months ago - Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
- 5 months ago - Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease - Benzinga
- 5 months ago - Belite Bio's drug for genetic eye disease meets main goal in late-stage trial - Reuters
- 5 months ago - New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease - GlobeNewsWire